Suchergebnisse - "Alcalá, Carmen"

PubPharm (72)

1

Eculizumab for a catastrophic relapse in NMOSD : case report

enthalten in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | 2024

von Gorriz, D. | Pérez-Miralles, F. | Quintanilla-Bordás, C. | +3

2

Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?

enthalten in: Multiple sclerosis and related disorders | 2023

von Ribes García, S. | Castillo-Villalba, J. | Gasque Rubio, R. | +5

3

Clinical Outcomes and Prognostic Factors of Patients With Early Malignant Melanoma in One Latin American Country : Results of the Epidemiological Registry of Malignant Melanoma in Colombia Study

enthalten in: JCO global oncology | 2023

von Ospina Serrano, A. | Contreras, F. | Triana, I. | +16

4

Impact of vaccination against COVID-19 on patients with cancer in ACHOC-C19 study : Real world evidence from one Latin American country

enthalten in: Journal of Cancer | 2023

von Ospina, A. | Brugés, R. | Triana, I. | +27

5

Treatment of multiple sclerosis with rituximab : A Spanish multicenter experience

enthalten in: Frontiers in neurology | 2023

von Gascón-Giménez, F. | Alcalá, C. | Ramió-Torrentà, L. | +19

6

Oligoclonal M bands unveil occult inflammation in multiple sclerosis

enthalten in: Multiple sclerosis and related disorders | 2022

von Casanova, B. | Castillo, J. | Quintanilla-Bordás, C. | +9

7

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis : a real-world observational study

enthalten in: Journal of neurology | 2022

von Alcalá, C. | Quintanilla-Bordás, C. | Gascón, F. | +15

8

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study

enthalten in: Journal of neurology | 2022

von Alcalá, C. | Quintanilla-Bordás, C. | Gascón, F. | +15

9

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study

enthalten in: Journal of neurology | 2022

von Alcalá, C. | Quintanilla-Bordás, C. | Gascón, F. | +15

10

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study

enthalten in: Journal of neurology | 2022

von Alcalá, C. | Quintanilla-Bordás, C. | Gascón, F. | +15

1
2
3
4
5
6
7
8
Nächster »
[8]